NMRA: Neumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
Stocks in this Quantisnow insightHealth Care
Historical context for NMRA
Across the 4 sessions after earlier NMRA headlines, the stock closed higher 2 times and lower 2 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NMRA | SPY |
|---|---|---|---|
| Jan 5, 2026 | Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestonesand 1 other headline that session | -1.5% | +0.7% |
| Dec 1, 2025 | Neumora Therapeutics upgraded by RBC Capital Mkts with a new price target | +8.0% | -0.5% |
| Nov 3, 2025 | Neumora Therapeutics to Participate in Upcoming Conferences in November | -0.3% | +0.2% |
| Oct 27, 2025 | Neumora Therapeutics upgraded by Guggenheim with a new price targetand 2 other headlines that session | +2.3% | +1.2% |
Keep researching NMRA
- What is Form 8-K?The SEC "current report" a public company files to disclose material events, generally within four business days of the event.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- NMRA insider tradesEvery buy and sale reported by Neumora Therapeutics Inc. officers, directors and large holders.
- NMRA financial statementsRevenue, profit, cash flow and balance sheet from Neumora Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
NMRA
Neumora Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2023
Get push alerts for NMRA
Full NMRA profile on Quantisnow Follow NMRA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time